<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014973</url>
  </required_header>
  <id_info>
    <org_study_id>2016/03</org_study_id>
    <secondary_id>2016-A00020-51</secondary_id>
    <nct_id>NCT03014973</nct_id>
  </id_info>
  <brief_title>Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status</brief_title>
  <acronym>HORM</acronym>
  <official_title>Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to determine the intra-prostatic concentration of sexual
      steroids when castration resistance appears in castration-resistant prostate cancer patients
      compared to patients naif of hormonal treatment
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intra-prostatic concentration of sexual steroids</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Androgen receptor immuno-histochemical expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen receptor RNA expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid 5-alphareductase immuno-histochemical expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid 5-alphareductase RNA expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid aromatase immuno-histochemical expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid aromatase RNA expression level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prostate cancer patients resistant to castration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients naif of hormonal treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intra-prostatic concentration of sexual steroids</intervention_name>
    <arm_group_label>prostate cancer patients resistant to castration</arm_group_label>
    <arm_group_label>patients naif of hormonal treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans-rectal biopsy</intervention_name>
    <arm_group_label>prostate cancer patients resistant to castration</arm_group_label>
    <arm_group_label>patients naif of hormonal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  group 1: patients with a locally advanced prostate cancer naif of any hormonal
             treatment

          -  group 2: Patients with a castration-resistant prostate cancer resisting defined by a
             biological progression

          -  group 2a: without radiotherapy

          -  group 2b: with radiotherapy

          -  Affiliated to a social security scheme

          -  Having given a written consent.

        Exclusion Criteria:

          -  Patient unable to supply a written consent (patient not understanding French, under
             guardianship patient).

          -  neuro-endocrine form or sarcomatoid form prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yann NEUZILLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Botto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yann NEUZILLET, MD</last_name>
    <phone>+33(0)146251961</phone>
    <email>y.neuzillet@hôpital-foch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann Neuzillet, MD</last_name>
      <phone>+33(0)146251961</phone>
      <email>y.neuzillet@hôpital-foch.org</email>
    </contact>
    <contact_backup>
      <last_name>Henry Botto, MD</last_name>
      <phone>+33(0)146252465</phone>
      <email>h.botto@hopital-foch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yann Neuzillet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Botto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

